SequelSEC

Neumora Therapeutics, Inc. NMRA

Biological Products, (No Diagnostic Substances) · CIK 0001885522 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$42.19M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Neumora Therapeutics, Inc. (NMRA) reported net income of -$43.08M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Neumora Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Neumora Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$42.19MUnavailable-$58.48M-$57.70MUnavailableUnavailable-$62.92M-$76.65MUnavailableUnavailable
Net income-$43.08MUnavailable-$59.45M-$56.76MUnavailableUnavailable-$58.82M-$72.55MUnavailableUnavailable
Research & development$29.28MUnavailable$44.67M$40.52MUnavailableUnavailable$45.91M$60.63MUnavailableUnavailable
Weighted-average diluted sharesshares 185.16MUnavailableUnavailableshares 161.84MUnavailableUnavailableUnavailableshares 159.58MUnavailableUnavailable
Pretax income-$43.08MUnavailable-$59.45M-$56.76MUnavailableUnavailable-$58.82M-$72.49MUnavailableUnavailable
Income tax expense$0Unavailable$0$0UnavailableUnavailable$0$53.00KUnavailableUnavailable
Diluted EPS$-0.23UnavailableUnavailable$-0.35UnavailableUnavailableUnavailable$-0.45UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$12.91MUnavailable$13.81M$12.18MUnavailableUnavailable$17.01M$16.02MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Neumora Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$116.83MUnavailable$182.53M$129.07MUnavailableUnavailable$142.15M$275.71MUnavailableUnavailable
Total assets$125.25MUnavailable$191.05M$177.83MUnavailableUnavailable$316.97M$352.54MUnavailableUnavailable
Current assets$124.87MUnavailable$190.54M$177.08MUnavailableUnavailable$314.06M$348.61MUnavailableUnavailable
Total liabilities$80.73MUnavailable$87.18M$45.67MUnavailableUnavailable$29.91M$31.80MUnavailableUnavailable
Current liabilities$27.78MUnavailable$32.45M$25.84MUnavailableUnavailable$29.89M$31.74MUnavailableUnavailable
Total equity incl. NCI$44.52MUnavailable$103.87M$132.16MUnavailableUnavailable$287.06M$320.74MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$52.91MUnavailable$54.53M$19.56MUnavailableUnavailable$0UnavailableUnavailableUnavailable
Accounts payable$4.15MUnavailable$3.38M$549.00KUnavailableUnavailable$3.31M$6.11MUnavailableUnavailable

Cash flow

Neumora Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$39.53MUnavailable-$47.96M-$46.63MUnavailableUnavailable-$50.34M-$33.48MUnavailableUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0Unavailable$42.65M$51.32MUnavailableUnavailable-$98.80M$156.99MUnavailableUnavailable
Financing cash flow$9.29MUnavailable$58.77M-$136.00KUnavailableUnavailable$15.57M$1.53MUnavailableUnavailable
Net change in cash-$30.24MUnavailable$53.46M$4.55MUnavailableUnavailable-$133.57M$125.04MUnavailableUnavailable
Stock-based compensation$7.18MUnavailable$7.41M$5.98MUnavailableUnavailable$9.90M$9.95MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$7.00KUnavailable$9.00K$23.00KUnavailableUnavailable$157.00K$156.00KUnavailableUnavailable

Derived

Neumora Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio4.50xUnavailable5.87x6.85xUnavailableUnavailable10.51x10.98xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity1.19xUnavailable0.52x0.15xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NMRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.